Auriga Reaffirms Sell Rating on AthenaHealth (ATHN)
AthenaHealth (NASDAQ: ATHN)‘s stock had its “sell” rating restated by analysts at Auriga in a research report issued to clients and investors on Monday.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray (NYSE: PJC) raised their price target on shares of AthenaHealth from $70.00 to $80.00 in a research note to investors on Sunday. They now have an “overweight” rating on the stock. Separately, analysts at Sterne Agee downgraded shares of AthenaHealth from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, February 28th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of AthenaHealth in a research note to investors on Friday, February 17th. They now have a $69.00 price target on the stock.
AthenaHealth traded up 3.73% on Monday, hitting $75.15. AthenaHealth has a 52-week low of $38.97 and a 52-week high of $78.24. The company has a market cap of $2.694 billion and a price-to-earnings ratio of 142.62.
The company last announced its quarterly results on Thursday, April 26th. It reported $0.17 earnings per share (EPS) for the previous quarter, meeting the Thomson Reuters consensus estimate of $0.17 EPS. The company’s quarterly revenue was up 38.1% on a year-over-year basis. Analysts expect that AthenaHealth will post $0.27 EPS next quarter.
athenahealth, Inc. (athenahealth) is a business services company that provides ongoing billing, clinical-related, and other related services to its customers.